Dr. Spira is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8613 Lee Highway
Fairfax, VA 22031Phone(703) 280-5390Fax(703) 280-9596- Is this information wrong?
Education & Training
- Johns Hopkins University School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2003
- University of Pennsylvania Health SystemResidency, Internal Medicine, 1997 - 2000
- NYU Grossman School of MedicineClass of 1997
Certifications & Licensure
- VA State Medical License 2003 - 2024
- MD State Medical License 2000 - 2003
- PA State Medical License 1998 - 2000
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:Washington DC Area Castle Connolly, 2012
- Top Doctors:Washington-Baltimore Castle Connolly, 2012
- Top MD Consumers Checkbook
Clinical Trials
- Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Start of enrollment: 2010 Jun 01
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
- A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 May 13
- 1 citationsA phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancerRuth Plummer, Emma Dean, Hendrik-Tobias Arkenau, Charles H. Redfern, Alexander I. Spira, Jason M. Melear, Ki Y. Chung, Jordi Ferrer-Playan, Thomas Goddemeier, Giuseppe...> ;Lung Cancer. 2021 Dec 1
- 10 citationsManagement of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.Bianca Santomasso, Loretta J. Nastoupil, Sherry Adkins, Christina Lacchetti, Bryan J. Schneider, Milan J. Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Cate...> ;Journal of Clinical Oncology. 2021 Nov 1
- Join now to see all
Journal Articles
- Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences
- Brigatinib Versus Crizotinib in ALK-Positive Non–Small-Cell Lung CancerD Ross Camidge, Scott N Gettinger, Alexander Spira, The New England Journal of Medicine
- Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAlexander I Spira, Helena A Yu, Clinical Lung Cancer
Abstracts/Posters
- Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...Alexander I. Spira, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...Alexander I. Spira, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Authored Content
- WCLC 2021: Study Improvements Mean Nothing Without PatientsFebruary 2021
- Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAugust 2018
Press Mentions
- Advanced Soft Tissue Sarcomas: Dox + Olaratumab vs. Dox + PBOJune 1st, 2019
- Insights on Tumor Growth Lead to New TreatmentsFebruary 24th, 2017
- Virginia Cancer Specialists Receives Clinical Trials Research Award from Conquer Cancer FoundationJuly 12th, 2016
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Inova Fair Oaks HospitalFairfax, Virginia
- Inova Fairfax HospitalFalls Church, Virginia
- Novant Health UVA Health Prince William Medical CenterManassas, Virginia
- Inova Loudoun HospitalLeesburg, Virginia
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: